Cost-Effectiveness of a New Fetal RHD Genotyping Test
Author Information
Author(s): Szczepura Ala, Osipenko Leeza, Freeman Karoline
Primary Institution: Warwick Medical School, University of Warwick, Coventry, UK
Hypothesis
Is non-invasive prenatal diagnosis (NIPD) cost-effective for targeting anti-D prophylaxis in RhD negative pregnancies?
Conclusion
NIPD testing for targeting anti-D prophylaxis is currently not cost-effective for large-scale implementation in England and Wales.
Supporting Evidence
- NIPD testing could lead to increased maternal sensitizations if not implemented carefully.
- Current anti-D prophylaxis policies are already effective in reducing sensitization rates.
- Cost savings from NIPD testing are minimal compared to the potential risks involved.
Takeaway
This study looked at a new test to see if it could save money when giving treatment to pregnant women. It found that the test might not be worth it because it could lead to more problems instead of saving money.
Methodology
An economic analysis comparing two scenarios of NIPD implementation against current policies.
Potential Biases
Potential bias due to reliance on existing data and assumptions about test performance and costs.
Limitations
The study's conclusions are limited by uncertainties regarding the royalty fees for NIPD tests and the reliability of NIPD in diverse populations.
Participant Demographics
Approximately 10% of pregnancies involve RhD negative mothers, with varying rates in different ethnic groups.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website